Applying biologic therapies to the management of patients with rheumatoid arthritis.
The challenge of providing uniformly effective rheumatoid arthritis care has thus far defied a simple solution. Variations in care range from the appropriate adjustment or switching of therapy subsequent to increased disease activity to the selection of therapeutic agent chosen following failure. This program is designed to improve the understanding of advances in immunopathologic discoveries that provide valuable aid in individualized treatment plans and the appropriate patient selection of available DMARDS and biologic therapeutics. Also, expert rheumatologists will discuss the latest data of head-to-head trials and recommendations for clinical effectiveness. This CME program will bring rheumatologists and other health care professionals up to date in managing their patients with rheumatoid arthritis.
University of Pennsylvania School of Medicine, Philadelphia, PA. Electronic address: mhochber@medicine.umaryland.edu.
Alan A
AA
Epstein
Albany Medical College, Albany, NY; The Center for Rheumatology, Albany, NY.
Joel M
JM
Kremer
Arthritis and Rheumatism Associates, Rockville, MD.
Evan
E
Siegel
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use*; D006801:Humans
D018501:Antirheumatic Agents; D001688:Biological Products